Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity (NASDAQ:ARAV) | Seeking Alpha
Form 8-K Aravive, Inc. For: Mar 03
Why Is Aravive (ARAV) Stock Down 52% Today? | InvestorPlace
SEC Filing | Aravive Biologics
Aravive, Inc. (ARAV) Stock Price, Quote & News - Stock Analysis
Form 8-K Aravive, Inc. For: Mar 03
ARAV - Aravive, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGS)
Articles about Aravive
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
slide-ixwd4kxaavh.jpg
WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis
1iawNXZOiiXMnZ90Z9a7fdTobm45fg17x.png?v=1701446619
Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity (NASDAQ:ARAV) | Seeking Alpha
Aravive, Inc.
Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity (NASDAQ:ARAV) | Seeking Alpha
Aravive, Inc. Aktie News
Aravive Inc. to delist from Nasdaq, plans liquidation - Houston Business Journal
Aravive, Inc. Aktie News
Aravive Announces $10.0 Million Inves... | ARAV Stock News
slide-bpyng1ahq2h.jpg
Home | Aravive, Inc.
Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity (NASDAQ:ARAV) | Seeking Alpha
Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity (NASDAQ:ARAV) | Seeking Alpha
Stephen Eck leaves Aravive CEO job to join Immatics | Fierce Biotech
Aravive Biologics and Versartis Complete Merger
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates
